Wave Life Sciences, Inc. (WVE) stock
WVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/3046% below fair value
$2.84−0.03 (-1.05%)
Close on Nov 17, 2026Market cap $560.13MP/E –Yield –
Wave Life Sciences total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
No total debt figures for Wave Life Sciences
Wave Life Sciences has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?